Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Objective. Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in the world. The pathogenesis of NAFLD is complex and multifactorial. Clinical studies have shown that alterations in the gut microbiota play a key role in NAFLD. The purpose of this study was to analyze the effect of probiotic supplementation on the treatment of NAFLD patients based on various indicators. Methods. We conducted a meta-analysis investigating the relationship between NAFLD and probiotic supplementation. Embase, PubMed, and Web of Science databases were searched by computer, and then, eligible studies were identified. Finally, a total of high-quality randomized controlled trials were selected involving 1403 participants. Meta-analysis was performed using the RevMan 5.3 software which was systematically searched for works published through Dec. 1, 2021, in the present study. Results. The meta-analysis results showed that the probiotics supplementation improved hepatocyte injury and significantly reduced the level of ALT ( P = 0.00001 ), AST ( P = 0.0009 ), GGT ( P = 0.04 ), TG ( P = 0.01 ), LDL-C ( P = 0.0005 ), HDL-C ( P = 0.0002 ), insulin ( P = 0.003 ), IR ( P = 0.03 ), BMI ( P = 0.03 ), TNF-α ( P = 0.03 ), and CRP ( P = 0.02 ), respectively, in NAFLD patients. Conclusion. The present study suggests that probiotics therapy may improve liver enzyme levels, regulated lipid metabolism, reduced insulin resistance, and improved inflammation in NAFLD patients. It supports the potential role of probiotics supplementation in the treatment of NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current understanding of the human microbiome
Gilbert, J. A., Blaser, M. J., Caporaso, J. G., Jansson, J. K., Lynch, S. V., & Knight, R. (2018) · Nature Medicine · doi:10.1038/nm.4517 · Cited by 2,609
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
Dysbiosis of the gut microbiota in disease
Carding, S., Verbeke, K., Vipond, D. T., Corfe, B. M., & Owen, L. J. (2015) · Microbial Ecology in Health & Disease · doi:10.3402/mehd.v26.26191 · Cited by 1,710 · cited 1×
“The metabolic function of microorganisms in the tract is disordered, and the number of pathogenic bacteria significantly increases [13].”
BackgroundThomas, A. M., Manghi, P., Asnicar, F., Pasolli, E., Armanini, F., Zolfo, M., Beghini, F., Manara, S., Karcher, N., Pozzi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0405-7 · Cited by 1,030 · cited 1×
“microbiota has become a potential therapeutic option for the treatment of NAFLD [30].”
BackgroundPage, M. J., & Moher, D. (2017) · Systematic Reviews · doi:10.1186/s13643-017-0663-8 · Cited by 769 · cited 1×
“Systematic review and meta-analysis were conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyse (PRISMA) guidelines to ensure the reliability and integrity of data and conclusions [18].”
MethodIntestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis
Tojo, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15163 · Cited by 533
Alisi, A., Bedogni, G., Baviera, G., Giorgio, V., Porro, E., Paris, C., Giammaria, P., Reali, L., Anania, F., & Nobili, V. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12758 · Cited by 471 · cited 1×
“Alisi [48] Italy 2014 24 (10/14) 4 months Liver biopsy VSL #3 Placebo 8”
BackgroundThe human microbiome in evolution
Davenport, E. R., Sanders, J. G., Song, S. J., Amato, K. R., Clark, A. G., & Knight, R. (2017) · BMC Biology · doi:10.1186/s12915-017-0454-7 · Cited by 393 · cited 1×
“Using 16S rRNA sequence analysis, differences in bacterial community structure were found in humans eating different diets [27].”
MethodCirculating leptin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Polyzos, S. A., Aronis, K. N., Kountouras, J., Raptis, D. D., Vasiloglou, M. F., & Mantzoros, C. S. (2016) · Diabetologia · doi:10.1007/s00125-015-3769-3 · Cited by 248
Sharpton, S. R., Schnabl, B., Knight, R., & Loomba, R. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.010 · Cited by 194 · cited 1×
“More and more researches are expanding our understanding of the mechanisms by which NAFLD is affected by gut microbes especially beneficial bacteria [42].”
Background
Cited by
Amini-Salehi, E., Hassanipour, S., Keivanlou, M.-H., Shahdkar, M., Orang Goorabzarmakhi, M., Vakilpour, A., Joukar, F., Hashemi, M., Sattari, N., Javid, M., et al. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuad086 · Cited by 42
Naghipour, A., Amini-Salehi, E., Orang Gorabzarmakhi, M., Shahdkar, M., Fouladi, B., Alipourfard, I., & Sanat, Z. M. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02299-x · Cited by 37
Mahapatro, A., Bawna, F., Kumar, V., Daryagasht, A. A., Gupta, S., Raghuma, N., Moghdam, S. S., Kolla, A., Mahapatra, S. S., Sattari, N., et al. (2023) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2023.07.087 · Cited by 37
Metadata
- Authors
- Huang, Y., Wang, X., Zhang, L., Zheng, K., Xiong, J., Li, J., Cong, C., Gong, Z., & Mao, J.
- Venue
- Computational and Mathematical Methods in Medicine
- Publisher
- Wiley
- Published
- 2022-05-30
- Volume
- 2022
- Pages
- 1-15
- ISSN
- 1748-670X (ISSN-L)
- 1748-6718
- OpenAlex
- W4281853964
- Cited by
- 44
- References
- 12
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease. https://app.cochat.ai/papers/10.1155/2022/7888076
- The paper
- Huang, Y., Wang, X., Zhang, L., Zheng, K., Xiong, J., Li, J., Cong, C., Gong, Z., & Mao, J. (2022). Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease. Computational and Mathematical Methods in Medicine. https://doi.org/10.1155/2022/7888076
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.